175 related articles for article (PubMed ID: 25882020)
1. [Potential clinical benefit of therapeutic drug monitoring of imatinib in oncology].
Turjap M; Juřica J; Demlová R
Klin Onkol; 2015; 28(2):105-11. PubMed ID: 25882020
[TBL] [Abstract][Full Text] [Related]
2. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Teng JF; Mabasa VH; Ensom MH
Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
[TBL] [Abstract][Full Text] [Related]
4. Drug plasma monitoring in CML and GIST: A case-based discussion.
Egorin MJ; Mauro MJ; Trent JC
Clin Adv Hematol Oncol; 2009 Nov; 7(11):S1, S3-11. PubMed ID: 20099379
[TBL] [Abstract][Full Text] [Related]
5. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
7. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
Guilhot F; Hughes TP; Cortes J; Druker BJ; Baccarani M; Gathmann I; Hayes M; Granvil C; Wang Y
Haematologica; 2012 May; 97(5):731-8. PubMed ID: 22315495
[TBL] [Abstract][Full Text] [Related]
8. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.
De Francia S; DʼAvolio A; Ariaudo A; Pirro E; Piccione F; Simiele M; Fava C; Calcagno A; Di Perri G; Saglio G
Ther Drug Monit; 2014 Jun; 36(3):410-2. PubMed ID: 24342895
[TBL] [Abstract][Full Text] [Related]
9. The role of imatinib plasma level testing in gastrointestinal stromal tumor.
George S; Trent JC
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S45-50. PubMed ID: 21140148
[TBL] [Abstract][Full Text] [Related]
10. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
11. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
Widmer N; Decosterd LA; Leyvraz S; Duchosal MA; Rosselet A; Debiec-Rychter M; Csajka C; Biollaz J; Buclin T
Br J Cancer; 2008 May; 98(10):1633-40. PubMed ID: 18475296
[TBL] [Abstract][Full Text] [Related]
12. Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A; Widmer N; Guidi M; Montemurro M; Leyvraz S; Buclin T; Eap CB; Decosterd LA; Csajka C
Br J Clin Pharmacol; 2013 Apr; 75(4):1007-18. PubMed ID: 22891806
[TBL] [Abstract][Full Text] [Related]
13. [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].
Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):177-82. PubMed ID: 22781602
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic myeloid leukemia with imatinib mesylate.
Ohno R
Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
Pavlovsky C; Egorin MJ; Shah DD; Beumer JH; Rogel S; Pavlovsky S
Pharmacotherapy; 2009 Sep; 29(9):1152-6. PubMed ID: 19698017
[TBL] [Abstract][Full Text] [Related]
16. Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel.
Yamazaki R; Aisa Y; Mori T; Iketani O; Ikeda Y; Okamoto S
Leuk Lymphoma; 2009 Apr; 50(4):670-2. PubMed ID: 19373671
[No Abstract] [Full Text] [Related]
17. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of imatinib targeted delivery in human leukocytes.
Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
[TBL] [Abstract][Full Text] [Related]
19. 21st-century oncology: a tangled web.
Keating P; Cambrosio A
Lancet; 2013 Dec; 382(9909):e45-6. PubMed ID: 24350356
[No Abstract] [Full Text] [Related]
20. Imatinib mesylate in the treatment of gastrointestinal stromal tumour.
Steinert DM; McAuliffe JC; Trent JC
Expert Opin Pharmacother; 2005 Jan; 6(1):105-13. PubMed ID: 15709888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
